Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

27.40USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$27.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,986,339
52-wk High
$29.92
52-wk Low
$23.30

Select another date:

Thu, Jan 11 2018

BRIEF-Boston Scientific Receives U.S. FDA Approval For Spectra Wavewriter Spinal Cord Stimulator System

* BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR SPECTRA WAVEWRITER™ SPINAL CORD STIMULATOR SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Boston Scientific Announces Preliminary Unaudited Sales For Q4 and FY17

* BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017

BRIEF-Boston Scientific Receives FDA Approval For Vercise Deep Brain Stimulation System

* BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE VERCISE™ DEEP BRAIN STIMULATION SYSTEM

BRIEF-Appaloosa LP cuts share stake in BofA, dissolves share stake in Wells Fargo and Activision Blizzard

* Appaloosa LP dissolves share stake in Activision Blizzard Inc - SEC filing

UPDATE 1-Boston Scientific hikes revenue forecast, boosted by acquisitions

Oct 26 U.S. medical device maker Boston Scientific Corp on Thursday hiked its annual revenue forecast, driven by recent acquisitions.

BRIEF-Boston Scientific announces results for third quarter 2017

* Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S

Boston Scientific's profit rises 24 pct in 3rd quarter

Oct 26 U.S. medical device maker Boston Scientific Corp's profit rose 24 percent in the third quarter, driven by growth across all its businesses.

BRIEF-Boston Scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary

* Boston scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary Source text for Eikon: Further company coverage:

BRIEF-Boston Scientific to buy Apama Medical

* Boston Scientific announces agreement to acquire Apama Medical

BRIEF-Boston Scientific announces positive late-breaking clinical trial data for Heartlogic Heart Failure Diagnostic

* Boston Scientific announces positive late-breaking clinical trial data for the Heartlogic Heart Failure Diagnostic Source text for Eikon: Further company coverage:

Select another date: